High-level copy number gains of established and potential drug target genes in gastric cancer as a lead for treatment development and selection

Cellular Oncology

Volumn 37, Issue 1, 2014, Pages 41-52

  Labots, Mariette ^a   Buffart, Tineke E ^a   Haan, Josien C ^a   Van Grieken, Nicole C T ^a   Tijssen, Marianne ^a   Van De Velde, Cornelis J H ^b   Grabsch, Heike I ^c   Ylstra, Bauke ^a   Carvalho, Beatriz ^a   Fijneman, Remond J A ^a   Verheul, Henk M W ^a   Meijer, Gerrit A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

DNA copy number changes; Drug repositioning; Drug target gene; Gastric cancer; Personalized medicine; Treatment selection

Indexed keywords

ANTINEOPLASTIC AGENTS; CLUSTER ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR TARGETED THERAPY; REPRODUCIBILITY OF RESULTS; STOMACH NEOPLASMS; TRANSCRIPTOME;

EID: 84894489940     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-013-0162-4     Document Type: Article

References (53)

1. D. Cunningham, N. Starling, S. Rao, T. Iveson, M. Nicolson, F. Coxon, G. Middleton, F. Daniel, J. Oates, A.R. Norman, Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358, 36-46 (2008)
2. E. Van Cutsem, V.M. Moiseyenko, S. Tjulandin, A. Majlis, M. Constenla, C. Boni, A. Rodrigues, M. Fodor, Y. Chao, E. Voznyi, M.L. Risse, J.A. Ajani, Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J. Clin. Oncol. 24, 4991-4997 (2006) (Pubitemid 46631401)
3. A.D. Wagner, S. Unverzagt, W. Grothe, G. Kleber, A. Grothey, J. Haerting, W.E. Fleig, Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev., CD004064 (2010)
4. A.D. Wagner, W. Grothe, J. Haerting, G. Kleber, A. Grothey, W.E. Fleig, Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J. Clin. Oncol. 24, 2903-2909 (2006) (Pubitemid 46630593)
5. V. Catalano, F. Graziano, D. Santini, S. D'Emidio, A.M. Baldelli, D. Rossi, B. Vincenzi, P. Giordani, P. Alessandroni, E. Testa, G. Tonini, G. Catalano, Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? Br. J. Cancer 99, 1402-1407 (2008)
6. P.C. Thuss-Patience, A. Kretzschmar, D. Bichev, T. Deist, A. Hinke, K. Breithaupt, Y. Dogan, B. Gebauer, G. Schumacher, P. Reichardt, Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur. J. Cancer 47, 2306-2314 (2011)
7. S.J. Gong, C.J. Jin, S.Y. Rha, H.C. Chung, Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Cancer Lett. 214, 215-224 (2004) (Pubitemid 39207983)
8. K. Fujimoto-Ouchi, F. Sekiguchi, H. Yasuno, Y. Moriya, K. Mori, Y. Tanaka, Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother. Pharmacol. 59, 795-805 (2007) (Pubitemid 46440603)
9. H. Grabsch, S. Sivakumar, S. Gray, H.E. Gabbert, W. Muller, HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value-conclusions from 924 cases of two independent series. Cell. Oncol. 32, 57-65 (2010)
10. C. Gravalos, A. Jimeno, HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann. Oncol. 19, 1523-1529 (2008)
11. M. Tanner, M. Hollmen, T.T. Junttila, A.I. Kapanen, S. Tommola, Y. Soini, H. Helin, J. Salo, H. Joensuu, E. Sihvo, K. Elenius, J. Isola, Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 16, 273-278 (2005) (Pubitemid 40309309)
12. Y.J. Bang, C.E. Van, A. Feyereislova, H.C. Chung, L. Shen, A. Sawaki, F. Lordick, A. Ohtsu, Y. Omuro, T. Satoh, G. Aprile, E. Kulikov, J. Hill, M. Lehle, J. Ruschoff, Y.K. Kang, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687-697 (2010)
13. H.H. Hartgrink, C.J. van de Velde, H. Putter, J.J. Bonenkamp, K.E. Klein, I. Songun, K. Welvaart, J.H. van Krieken, S. Meijer, J.T. Plukker, P.J. van Elk, H. Obertop, D.J. Gouma, J.J. van Lanschot, C.W. Taat, P.W. de Graaf, M.F. von Meyenfeldt, H. Tilanus, M. Sasako, Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J. Clin. Oncol. 22, 2069-2077 (2004) (Pubitemid 41095139)
14. T.E. Buffart, B. Carvalho, N.C. van Grieken, W.N. van Wieringen, M. Tijssen, E.M. Kranenbarg, H.M. Verheul, H.I. Grabsch, B. Ylstra, C.J. van de Velde, G.A. Meijer, Losses of chromosome 5q and 14q are associated with favorable clinical outcome of patients with gastric cancer. Oncologist 17, 653-662 (2012)
15. T.E. Buffart, N.C. van Grieken, M. Tijssen, J. Coffa, B. Ylstra, H.I. Grabsch, C.J. van de Velde, B. Carvalho, G.A. Meijer, High resolution analysis of DNA copy-number aberrations of chromosomes 8, 13, and 20 in gastric cancers. Virchows Arch. 455, 213-223 (2009)
16. R.P. Brosens, J.C. Haan, B. Carvalho, F. Rustenburg, H. Grabsch, P. Quirke, A.F. Engel, M.A. Cuesta, N. Maughan, M. Flens, G.A. Meijer, B. Ylstra, Candidate driver genes in focal chromosomal aberrations of stage II colon cancer. J. Pathol. 221, 411-424 (2010)
17. A.S. Hinrichs, D. Karolchik, R. Baertsch, G.P. Barber, G. Bejerano, H. Clawson, M. Diekhans, T.S. Furey, R.A. Harte, F. Hsu, J. Hillman-Jackson, R.M. Kuhn, J.S. Pedersen, A. Pohl, B.J. Raney, K.R. Rosenbloom, A. Siepel, K.E. Smith, C.W. Sugnet, A. Sultan-Qurraie, D.J. Thomas, H. Trumbower, R.J. Weber, M. Weirauch, A.S. Zweig, D. Haussler, W.J. Kent, The UCSC genome browser database: update 2006. Nucleic Acids Res. 34, D590-D598 (2006)
18. M.A. Sanz, Treatment of acute promyelocytic leukemia. Hematology. Am. Soc. Hematol. Educ. Program., 147-155 (2006)
19. J. Voortman, J.H. Lee, J.K. Killian, M. Suuriniemi, Y. Wang, M. Lucchi, W.I. Smith Jr., P. Meltzer, Y. Wang, G. Giaccone, Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc. Natl. Acad. Sci. U. S. A. 107, 13040-13045 (2010)
20. N. Deng, L.K. Goh, H. Wang, K. Das, J. Tao, I.B. Tan, S. Zhang, M. Lee, J. Wu, K.H. Lim, Z. Lei, G. Goh, Q.Y. Lim, A.L. Tan, D.Y. Sin Poh, S. Riahi, S. Bell, M.M. Shi, R. Linnartz, F. Zhu, K.G. Yeoh, H.C. Toh, W.P. Yong, H.C. Cheong, S.Y. Rha, A. Boussioutas, H. Grabsch, S. Rozen, P. Tan, A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61, 673-684 (2012)
21. A.M. Dulak, S.E. Schumacher, J. van Lieshout, Y. Imamura, C. Fox, B. Shim, A.H. Ramos, G. Saksena, S.C. Baca, J. Baselga, J. Tabernero, J. Barretina, P.C. Enzinger, G. Corso, F. Roviello, L. Lin, S. Bandla, J.D. Luketich, A. Pennathur, M. Meyerson, S. Ogino, R.A. Shivdasani, D.G. Beer, T.E. Godfrey, R. Beroukhim, A.J. Bass, Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res. 72, 4383-4393 (2012)
22. P. Seve, C. Dumontet, Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol. 9, 168-175 (2008) (Pubitemid 351150128)
23. P. Seve, J. Mackey, S. Isaac, O. Tredan, P.J. Souquet, M. Perol, R. Lai, A. Voloch, C. Dumontet, Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol. Cancer Ther. 4, 2001-2007 (2005) (Pubitemid 43056983)
24. G. Ferrandina, G.F. Zannoni, E. Martinelli, A. Paglia, V. Gallotta, S. Mozzetti, G. Scambia, C. Ferlini, Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin. Cancer Res. 12, 2774-2779 (2006)
25. A. Paradiso, A. Mangia, A. Chiriatti, S. Tommasi, A. Zito, A. Latorre, F. Schittulli, V. Lorusso, Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann. Oncol. 16 Suppl 4, iv14-iv19 (2005) (Pubitemid 43084940)
26. N. Urano, Y. Fujiwara, Y. Doki, S.J. Kim, Y. Miyoshi, S. Noguchi, H. Miyata, S. Takiguchi, T. Yasuda, M. Yano, M. Monden, Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int. J. Oncol. 28, 375-381 (2006)
27. S.Y. Kanta, T. Yamane, Y. Dobashi, F. Mitsui, K. Kono, A. Ooi, Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Hum. Pathol. 37, 1333-1343 (2006) (Pubitemid 44380283)
28. Z. Liang, X. Zeng, J. Gao, S. Wu, P. Wang, X. Shi, J. Zhang, T. Liu, Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer 8, 363 (2008)
29. A. Webb, D. Cunningham, J.H. Scarffe, P. Harper, A. Norman, J.K. Joffe, M. Hughes, J. Mansi, M. Findlay, A. Hill, J. Oates, M. Nicolson, T. Hickish, M. O'Brien, T. Iveson, M. Watson, C. Underhill, A. Wardley, M. Meehan, Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J. Clin. Oncol. 15, 261-267 (1997) (Pubitemid 27020582)
30. S. Corporaal, W.M. Smit, M.G. Russel, J. van der Palen, H. Boot, M.C. Legdeur, Capecitabine, epirubicin and cisplatin in the treatment of oesophagogastric adenocarcinoma. Neth. J. Med. 64, 141-146 (2006) (Pubitemid 43772037)
31. A.H. Marx, L. Tharun, J. Muth, A.M. Dancau, R. Simon, E. Yekebas, J.T. Kaifi, M. Mirlacher, T.H. Brummendorf, C. Bokemeyer, J.R. Izbicki, G. Sauter, HER-2 amplification is highly homogenous in gastric cancer. Hum. Pathol. 40, 769-777 (2009)
32. C. Bozzetti, F.V. Negri, C.A. Lagrasta, P. Crafa, C. Bassano, I. Tamagnini, G. Gardini, R. Nizzoli, F. Leonardi, D. Gasparro, R. Camisa, S. Cavalli, E.M. Silini, A. Ardizzoni, Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br. J. Cancer 104, 1372-1376 (2011)
33. J.T. Jorgensen, Targeted HER2 treatment in advanced gastric cancer. Oncology 78, 26-33 (2010)
34. A. Varis, A. Zaika, P. Puolakkainen, B. Nagy, I. Madrigal, A. Kokkola, A. Vayrynen, P. Karkkainen, C. Moskaluk, W. El-Rifai, S. Knuutila, Coamplified and overexpressed genes at ERBB2 locus in gastric cancer. Int. J. Cancer 109, 548-553 (2004) (Pubitemid 38339645)
35. M.F. Press, G. Sauter, M. Buyse, L. Bernstein, R. Guzman, A. Santiago, I.E. Villalobos, W. Eiermann, T. Pienkowski, M. Martin, N. Robert, J. Crown, V. Bee, H. Taupin, K.J. Flom, I. Tabah-Fisch, G. Pauletti, M.A. Lindsay, A. Riva, D.J. Slamon, Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J. Clin. Oncol. 29, 859-867 (2011)
36. L.A. Di, C. Desmedt, J.M. Bartlett, F. Piette, B. Ejlertsen, K.I. Pritchard, D. Larsimont, C. Poole, J. Isola, H. Earl, H. Mouridsen, F.P. O'Malley, F. Cardoso, M. Tanner, A. Munro, C.J. Twelves, C. Sotiriou, L. Shepherd, D. Cameron, M.J. Piccart, M. Buyse, HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol. 12, 1134-1142 (2011)
37. A.F. Okines, L.C. Thompson, D. Cunningham, A. Wotherspoon, J.S. Reis-Filho, R.E. Langley, T.S. Waddell, D. Noor, Z. Eltahir, R. Wong, S. Stenning, Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Ann. Oncol. 24, 1253-1261 (2013)
38. T. Deng, J.C. Liu, K.I. Pritchard, A. Eisen, E. Zacksenhaus, Preferential killing of breast tumor initiating cells by N, N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine/tesmilifene. Clin. Cancer Res. 15, 119-130 (2009)
39. L. Reyno, L. Seymour, D. Tu, S. Dent, K. Gelmon, B. Walley, A. Pluzanska, V. Gorbunova, A. Garin, J. Jassem, T. Pienkowski, J. Dancey, L. Pearce, M. MacNeil, S. Marlin, D. Lebwohl, M. Voi, K. Pritchard, Phase III study of N, N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. J. Clin. Oncol. 22, 269-276 (2004) (Pubitemid 41095091)
40. I.J. Waterman, V.A. Zammit, Differential effects of fenofibrate or simvastatin treatment of rats on hepatic microsomal overt and latent diacylglycerol acyltransferase activities. Diabetes 51, 1708-1713 (2002) (Pubitemid 34564281)
41. I.R. Konings, A. van der Gaast, L.J. van der Wijk, F.E. de Jongh, F.A. Eskens, S. Sleijfer, The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial. Eur. J. Cancer 46, 3200-3204 (2010)
42. L. Gong, R.B. Altman, T.E. Klein, Bisphosphonates pathway. Pharmacogenet. Genomics 21, 50-53 (2011)
43. G. Chen, M. Rong, D. Luo, TNFRSF6B neutralization antibody inhibits proliferation and induces apoptosis in hepatocellular carcinoma cell. Pathol. Res. Pract. 206, 631-641 (2010)
44. V. Brinkmann, A. Billich, T. Baumruker, P. Heining, R. Schmouder, G. Francis, S. Aradhye, P. Burtin, Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9, 883-897 (2010)
45. B.J. Tan, B.H. Tan, G.N. Chiu, Effect of triptolide on focal adhesion kinase and survival in MCF-7 breast cancer cells. Oncol. Rep. 26, 1315-1321 (2011)
46. S. Lapenna, A. Giordano, Cell cycle kinases as therapeutic targets for cancer. Nat. Rev. Drug Discov. 8, 547-566 (2009)
47. A. Ohtsu, M.A. Shah, C.E. Van, S.Y. Rha, A. Sawaki, S.R. Park, H.Y. Lim, Y. Yamada, J. Wu, B. Langer, M. Starnawski, Y.K. Kang, Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J. Clin. Oncol. 29, 3968-3976 (2011)
48. E. Van Cutsem, S. de Haas, Y.K. Kang, A. Ohtsu, N.C. Tebbutt, X.J. Ming, Y.W. Peng, B. Langer, P. Delmar, S.J. Scherer, M.A. Shah, Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J. Clin. Oncol. 30, 2119-2127 (2012)
49. S.A. Lang, D. Klein, C. Moser, A. Gaumann, G. Glockzin, M.H. Dahlke, W. Dietmaier, U. Bolder, H.J. Schlitt, E.K. Geissler, O. Stoeltzing, Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol. Cancer Ther. 6, 1123-1132 (2007) (Pubitemid 46554583)
50. L. Xie, X. Su, L. Zhang, X. Yin, L. Tang, X. Zhang, Y. Xu, Z. Gao, K. Liu, M. Zhou, B. Gao, D. Shen, L. Zhang, J. Ji, P.R. Gavine, J. Zhang, E. Kilgour, X. Zhang, Q. Ji, FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin. Cancer Res. 19, 2572-2583 (2013)
51. J. Lee, J.W. Seo, H.J. Jun, C.S. Ki, S.H. Park, Y.S. Park, H.Y. Lim, M.G. Choi, J.M. Bae, T.S. Sohn, J.H. Noh, S. Kim, H.L. Jang, J.Y. Kim, K.M. Kim, W.K. Kang, J.O. Park, Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol. Rep. 25, 1517-1524 (2011)
52. M. Nakajima, H. Sawada, Y. Yamada, A. Watanabe, M. Tatsumi, J. Yamashita, M. Matsuda, T. Sakaguchi, T. Hirao, H. Nakano, The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85, 1894-1902 (1999) (Pubitemid 29202761)
53. Y.Y. Janjigian, L.H. Tang, D.G. Coit, D.P. Kelsen, T.D. Francone, M.R. Weiser, S.C. Jhanwar, M.A. Shah, MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol. Biomarkers Prev. 20, 1021-1027 (2011)